Abstract
The drugs used to treat neoplasms are considered systemic treatments and thus they can reach any cell in the body, especially those proliferating quickly, thus leading to adverse effects so feared by patients. Toxicity will depend on several factors, including the condition of the individual, stage of the disease, and also the drugs used (Burille et al., Manejo e enfrentamento dos efeitosadversospelosclientesemtratamentoquimioterápico. RevistaCiência, Cuidado e Saúde, 7. https://periodicos.uem.br/ojs/index.php/CiencCuidSaude/article/view/6707 Accessed on 29/06/2021, 2013). Upon the points discussed, it is possible to understand that there is a need to expand knowledge regarding the management of adverse effects experienced by patients undergoing chemotherapy. The purpose is to assist them properly because they can present several adverse effects in varying degrees of intensity (Soares et al., CogitareEnferm, 14(4):714–719, 2009). The drugs offered as support are essential in managing these effects, helping to improve the quality of life of patients and greater adherence to cancer treatment (França et al., Einstein, 13(2):221–225, 2015).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Weiss RB, Baker JR. Hypersensitivity reactions from antineoplastic agents. Cancer Metas Rev. 1987;6:413–32.
Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263–1268 9782.
Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601–9.
Calogiuri G, Ventura MT, Mason L, et al. Hypersensitivity reactions to last generation chimeric, humanized, and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des. 2008;14:2883–91.
Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev. 1999;18:465–71.
Brennan PJ, Bouza TR, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mABs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259–66.
Ream MA, Tunison D. Hypersensitivity reactions. In: Yasko JM, editor. Nursing Management of Symptoms Associated with chemotherapy. Meniscus Health Care: Bala Cynwyd; 2001. p. 213–24.
Darmon M, Malak S, Guichard I, Schlemmer B. Acute tumor lysis syndrome: a comprehensive review. Rev Bras Ter Intensiva. 2008;20(3):278–85.
Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol. 2005;147:61–8.
Montesinos P, Lorenzo I, Martín G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93(1):67–74.
Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with highgrade non-Hodgkin’s lymphoma. Am J Med. 1993;94(2):133–9.
Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–54.
Tallo FS, Vendrame LS, Lopes RD, Lopes AC. Síndrome da lise tumoral: umarevisão para o clínico. Rev Bras Clin Med. São Paulo. 2013;11(2):150–4.
Solh M, Appel J. Tumor lysis syndrome. Hosp Physician. 2008;44:25–9.
Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on the management of tumor lysis syndrome. Hema. 2008;93(12):1877–85.
Coiffier BA, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767–78.
Montoya L. Managing hematologic toxicities in the oncology patient. J Infus Nurs. 2007;30(3):168–72.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: fever and neutropenia. Available at: http://www.nccn.org/professionals/physician_gls/PDF/fever.pdf. Accessed 13 June 2021.
Foubert J. Cancer-related anaemia and fatigue: assessment and treatment. Nurs Stand. 2013;20(36):50.
Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322(24):1689–92.
Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3):13–9.
Kuter DJ. Managing thrombocytopenia associated with câncer chemotherapy. Oncology. 2015;29(4):282.
Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–51.
Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;44(8):453–5.
Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst R. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11(1):1–11.
Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40(15):2201–16.
Organização Pan Americana de SaúdeBrasil. Folha informativa – Câncer. https://www.paho.org/bra/index.php?option=com_content&view=article&id=5588:folha-informativa-cancer&Itemid=1094. Acessoem 22 de julho.
O’Brien BJ, Rusthoven J, Rocchi A, Latreille J, Fine S, Vandenberg T, Laberge F. Impact of chemoterapy – associated nausea and vomiting on patients functional status and on costs: survey of five Canadian centers. Can Med Assocj. 1993;149(3):296–302.
Fresco DR, Suárez L. Recomendaciones para la prevención y eltratamento de náuseas y vómitosinducidos por quimioterapia. Revista Medica del Uruguay. 2004;20(2):120–9.
Hu Z, Liang W, Yang Y, et al. Personalized estimate of chemoterapy-induced nausea and vomiting: development and external validation of a nomogram in cancer patients receiving highly/moderately emetogenic chemoterapy. Medicine. 2016;95(2) https://journals.lww.com/md-journal/Fulltext/2016/01120/Personalized_Estimate_of_Chemotherapy_Induced.58.aspx Accessed July 22.
Becker J, Nardin JM. Use of antiemetics in the antineoplastic treatment of cancer patients. R Bras Farm Hosp Serv Saúde São Paulo. 2011;2(3):18–22.
Almeida RGL, Pontes ACAA, Cardoso DA, Carrera JS, Sousa MS, Maia SF. O Manejo da ÊmeseemumaUnidadeOncológica: a Necessidade da IntervençãoFarmacêuticaem Tempo Real. RevistaBrasileira de Cancerologia. 2015;61(2):115–21.
Aapro M, Jordan K, and Feyer P. 2013. Pathophysiology of chemotherapy-induced nausea and vomiting. https://link.springer.com/chapter/10.1007%2F978-1-907673-58-0_2.
National Comprehensive Cancer Network (NCCN) Guidelines. Antiemesis, version 1.2019, 2019.
Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100(10):2261–8.
Guia para notificação de reaçõesadversasemoncologia/SociedadeBrasileira de FarmacêuticosemOncologia – SOBRAFO, Agência Nacional de VigilânciaSanitária – ANVISA. 2. ed. São Paulo: ConectfarmaPublicaçõesCientíficas; 2011.
Barrios DM, Phillips GS, Freites-Martinez A, et al. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol. 2020;34(6):1340–7.
Lacouture ME, Sibaud V, Gerber PA, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆. Ann Oncol. 2021;32(2):157–70.
Nardone B, Nicholson K, Newman M, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitop.rs in cancer patients. Clin Cancer Res. 2010;16:4452–60.
Saad ED, Hoff PM, Carnelós RP, et al. Comun toxicity criteria of the National Cancer Institute. Revista Brasileira de Cancerologia. 2002;48(1):63–96.
Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med. 2013;5:111.
Roe E, Garcia Muret MP, Marcuello E, et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol. 2006;55:429–37.
Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19:1079–95.
Zhao CY, Liu RC, Consuegra G, et al. Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone. Australas J Dermatol. 2018;59:219–20.
Jo SJ, Shin H, Jo S, et al. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand–foot syndrome during chemotherapy: a meta-analysis. Clin Exp Dermatol. 2015;40(3):260–70.
Zhang RX, Wu XJ, Wan DS, et al. Celecoxib can prevent capecitabine related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. 2012;23:1348–53.
Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71:787–94.
Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, openlabel, randomised, phase 3 trial. Lancet Oncol. 2018;19:1315–27.
Anforth R, Fernandez-Penas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol. 2013;14:11–8.
Zielinski C, Lang I, Beslija S, et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. Br J Cancer. 2016;114:163–70.
Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U. et al., Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer. 2011;105(2):206–11.
Freites-Martinez A, Azael. The MASCC textbook of cancer supportive care and survivorship. New York: Springer International Publishing; 2018. p. 2018.
Sibaud V, Leboeuf NR, Roche H, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016;26:427–43.
Stander S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the international forum for the study of itch. Acta Derm Venereol. 2007;87:291–4.
Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine,and placebo in chronic idiopathic urticaria and atopic dermatitis. ClinTher. 1992;14:17–21.
Robert C, Sibaud V, Mateus C, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16:181–9.
Kiyohara Y, Yamazaki N, Kishi A. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer. J Am Acad Dermatol. 2013;69:463–72.
Piraccini BM, Bellavista S, Misciali C, et al. Periungual and subungual pyogenic granuloma. Br J Dermatol. 2010;163:941–53.
Capriotti K, Capriotti JA. Chemotherapy-associated paronychia treated with a dilute povidone-iodine/dimethylsulfoxide preparation. Clin CosmetInvestig Dermatol. 2015;8:489–91.
Capriotti K, Capriotti J, Pelletier J, et al. Chemotherapy-associated paronychia treated with 2% povidone-iodine: a series of cases. Cancer Manag Res. 2017;9:225–8.
Cubiro X, Planas-Ciudad S, Garcia-Muret MP, et al. Topical timolol for paronychia and pseudopyogenic granuloma in patients treated with epidermal growth factor receptor inhibitors and capecitabine. JAMA Dermatol. 2018;154:99–100.
Mirshams M, Daneshpazhooh M, Mirshekari A, et al. Cryotherapy in the treatment of pyogenic granuloma. J Eur Acad Dermatol Venereol. 2006;20:788–90.
Winther D, Saunte DM, Knap M, et al. Nail changes due to docetaxelda neglected side effect and nuisance for the patient. Support Care Cancer. 2007;15:1191–7.
Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2012;67:400–8.
Minisini AM, Tosti A, Sobrero AF, et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol. 2003;14:333–7.
Thomas R, Williams M, Cauchi M, et al. A double-blind, randomised trial of a polyphenolic-rich nail bed balm for chemotherapy-induced onycholysis: the UK polybalm study. Breast Cancer Res Treat. 2018;171:103–10.
Kim JY, Ok ON, Seo JJ, et al. A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy. Breast Cancer Res Treat. 2017;164:617–25.
Scotte F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23:4424–9.
Scotte F, Banu E, Medioni J, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008;112:1625–31.
Bossi P, Antonuzzo A, Cherny NI, et al. ESMO guidelines committee. Electronic address: clinicalguidelines@esmo.org. Diarrhea in adult cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(4):126–42.
Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15(10):447–60.
Benson AB III, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918–26.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
da Silva, G.S., Fernandes, L.L., Pereira, T.T. (2022). Support Drugs. In: Schmidt, C.W.P., Otoni, K.M. (eds) The Golden Guide to Oncologic Pharmacy. Springer, Cham. https://doi.org/10.1007/978-3-030-98596-7_10
Download citation
DOI: https://doi.org/10.1007/978-3-030-98596-7_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-98595-0
Online ISBN: 978-3-030-98596-7
eBook Packages: MedicineMedicine (R0)